Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
- Posted on June 2, 2026
- By CNBC
- 0 Views
- 1 min read
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
